3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
4
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Gynecologic
4
Genitourinary
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
57
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
Paclitaxel
71
Bevacizumab
64
Carboplatin
56
pembrolizumab
46
olaparib
32
Gemcitabine
29
Specimen Handling
27
Cyclophosphamide
26
liposomal doxorubicin
24
Magnetic Resonance Spectroscopy
24
Cisplatin
22
niraparib
21
Taxes
19
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
13
Disulfides
13
Fulvestrant
12
Blood Specimen Collection
11
durvalumab
10
Oxaliplatin
10
mirvetuximab soravtansine
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled
NCT07340164
2026-04-20
TROY
Yonsei University
Phase 2
Recruiting
116 enrolled